Relay Therapeutics, Inc. (RLAY) Tops Q2 EPS by 8c

Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q2 EPS of ($0.41), $0.08 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $66.67 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• DOJ Unveils $6.5B Healthcare Fraud Crackdown - WSJ
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance